Rutgers Center for State Health Policy June 28, 2005 Presentation to the Academy Health Kimberley Fox, Senior Policy Analyst Rutgers Center for State Health.

Slides:

Advertisements

Similar presentations

K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Figure 0 The Transition of Dual Eligibles to Medicare Drug Coverage: Implications for Beneficiaries.

Advertisements

1 Filling the Holes in Part D: SPAPs to the Rescue? Marc Steinberg, Families USA Health Action 2005 * January 27,

DataBrief: Did you know… DataBrief Series ● February 2011 ● No. 12 Dual Eligibles Across the States In 2008, dual eligibles as a percent of the total Medicare.

What does REMI say? sm Medicaid Expansion; Are You In or Are You Out? Presented by Chris Brown Senior Economic Associate.

Adam J. Falk, Esq. FELDESMAN TUCKER LEIFER FIDELL LLP Legal issues for Medicaid Plans Under Part D in Serving Dual Eligibles MEDICAID HEALTH PLANS OF AMERICA.

Challenges of Serving Low-income Medicare Beneficiaries: Impact of Cost Sharing Cindy Parks Thomas Brandeis University Schneider Institute for Health Policy.

Coordination of Benefits and TrOOP Tracey McCutcheon Center for Beneficiary Choices CMS.

New York State EPIC Program January 2012 Changes.

Supplementing PACE through Medicare Part D

North Carolina AIDS Drug Assistance Program (ADAP) State Pharmaceutical Assistance Program (SPAP)

Medicare Part D and HIV/AIDS: What a Clinician May Want to Know Laura Cheever, M.D., ScM Deputy Director, Chief Medical Officer HIV/AIDS Bureau Health.

THE AIDS INSTITUTE The AIDS Institute HEALTH REFORM AND ADAP Emily McCloskey, Public Policy Associate Carl Schmid, Deputy Executive Director AIDS Drug.

© 2014 Medicare Rights Center Let’s Learn Medicare Programs that Help Pay Your Medicare Costs.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health? Get Educated, Get Enrolled An.

Section 5: Public Health Insurance Programs Medicare Medical Assistance (Medicaid) MinnesotaCare General Assistance Medical Care (GAMC) Minnesota Comprehensive.

Return to KaiserEDU Tutorials

Medicare and the New Prescription Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser.

Medicare Part D Overview of Options, Creditable Coverage, Required Notices, COB and Health Care Reform.

Part D Data Sharing Harry Gamble Office of Financial Management CMS.

Joint Informational Hearing The Federal Medicare Prescription Drug Act: State Readiness, Implementation, and Consumer Issues Bonnie Burns, Training and.

MEDICARE PRESCRIPTION DRUG BENEFIT Presented by Juliette Cubanski, Ph.D. Principal Policy Analyst Medicare Policy Project The Henry J. Kaiser Family Foundation.

Maximizing the Medicare Drug Discount Card Subsidy and Part-D State Implementation Status Update Web-conference December 16, :30 – 5:00 pm EST 3:30.

1 State Perspectives on Medicare Part D: Lessons from Pharmacy Plus Programs Cindy Parks Thomas Donald Shepard Christine E. Bishop Daniel M. Gilden Brandeis.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health?

Medicare in Minnesota 2012 Your Medicare: Making the Best Possible Decisions October 2011 Presented by Stephanie Minor Senior LinkAge Line® Program Consultant.

Medicare Prescription Drug Benefit: Part D Health & Disability Advocates Stephanie Altman, J.D Ext

Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Roy Trudel, CMSO National Eligibility Workers Association 07/12/05.

What’s in the Mail? Overview of Medicare Prescription Drug Coverage Beneficiary Communications Employer Forum Conference Call October 13, 2005.

MEDICARE PART D Are We Ready? Are We Ready?. Medicare Part D Overview Medicare Part A and B covers individuals Age 65 and older Age 65 and older Those.

What Difference Will It Make for People with Disabilities? Michael Dalto Maryland Department of Disabilities December 8,

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy.

January National Medicare & You Training Program Amy Larrick, CMS NAACP April 27, 2006.

Medicare, Medicaid, and Health Care Reform Todd Gilmer, PhD Professor of Health Policy and Economics Department of Family and Preventive Medicine 1.

1 MEDICARE ADVANTAGE PLANS: MEDICARE COSTS IN 2007 Brian Biles, MD, MPH Department of Health Policy George Washington University June 3, 2007.

Medicare and Patient Assistance Sean M. Dougherty Senior Director Medicare Strategy & Patient Assistance Programs Government, Public Policy And Managed.

Impact of the MMA on Dual Eligible Beneficiaries and State Medicaid Programs Joy Johnson Wilson, Health Policy Director, NCSL June 28, 2005.

K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Figure 0 Robin Rudowitz Associate Director Kaiser Commission on Medicaid and the Uninsured.

Commonwealth of Massachusetts Executive Office of Health and Human Services Implementing the Affordable Care Act in Massachusetts 2012 Legislative Changes.

The New Medicare Prescription Drug Benefit: An Overview Prepared by: Michelle Kitchman, M.H.S. Kaiser Family Foundation For the: California Senate Health.

11/8/051 Medicare Prescription Drug Benefits Employee Workshop November 2005.

0 Beneficiary Choices in Medicare Part D and Plan Features in 2006 Supported by PhRMA September 13, 2006.

Avalere Health LLC | The intersection of business strategy and public policy The Potential Impact of the New Prescription Drug Benefit on Medicare Beneficiaries.

Finance Team National Hispanic Medical Association Leadership Fellowship 2003 Jose Castro MD Elsa Escalera MD Inginia Genao MD Advisor: Charles Brecher.

Ian D. Spatz Merck & Co., Inc. January 14, 2004 Ian D. Spatz Merck & Co., Inc. January 14, 2004 Overview of the New Medicare Prescription Drug Law.

K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Figure 0 Medicare Modernization Act of 2003: Implications for Low-Income People and State.

The Potential Impact of Health Care Reform on California: Consumer Affordability Dylan H. Roby, Ph.D. Assistant Professor of.

Avalere Health LLC | The intersection of business strategy and public policy The Medicare Modernization Act: The Impact on States and Low-Income Beneficiaries.

Implications of the 2003 Medicare law for older adults and people with disabilities Translating “Legislative Sausage” into Understandable Choices Diane.

Figure 1 K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Dual Eligibles: The Basics Barbara Lyons, Ph.D. Director, Kaiser Commission on.

1 Cost Sharing for Low-Income Beneficiaries and Supplementing Part D Examples from Pharmacy Plus Medicaid Demonstration Programs Summit for State Health.

1 Medicare Reform: Implications for Pharmaceutical Manufacturers G. Lawrence Atkins, PhD Schering-Plough Corporation January 14, 2004.

Karissa A. Laur Director, Prescription Assistance Programs Coordinating Patient Assistance Programs with Medicare Part D: A Manufacturer’s Perspective.

Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Deirdre Duzor Director, Pharmacy Division Centers for Medicare & Medicaid Services.

1 State Options for Supplementing Medicare Part D Drug Coverage Invitational Summit on Medicare Part D Implementation Issues Jack Hoadley Georgetown University.

Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.

Estimating the Cost of the Medicare Drug Benefit Philip Ellis Steve Lieberman Medicare Prescription Drug Congress February 27, 2004.

National Conference of State Legislatures National Medicaid Congress June 5, 2006 State Pharmaceutical Assistance Programs, Medicaid & Part D: 2006 State.

Avalere Health LLC | The intersection of business strategy and public policy Enrollment in the Medicare Drug Benefit Medicare Congress Audioconference.

Avalere Health LLC | The intersection of business strategy and public policy The Impact of Enrollment in the Medicare Prescription Drug Benefit on Premiums.

State Responses to Medicare Part D Presented by: Kimberley Fox, Senior Policy Analyst, Institute for Health Policy Academy Health Annual Research Meeting.

Health Reform: An Overview Unit 4 Seminar. The Decision The opinions spanned 193 pages, upholding the individual insurance mandate while reflecting a.

Overview of the Medicare Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser Family.

Director, Pennsylvania PACE Program National Medicare Congress

Dual Eligibles Across the States

Third-Party Recovery as a Percentage of Total Drug Expenditures, 2003

Annual Drug Expenditures per User, 2003

Presented by Tricia Neuman, Sc.D.

Rebates as a Percentage of Total Drug Expenditures, 2003

Medicare Part D Implementation Issues: Key Decisions for States

Proportion of SPAP Drug Expenditures in Five States vs

Presentation transcript:

Rutgers Center for State Health Policy June 28, 2005 Presentation to the Academy Health Kimberley Fox, Senior Policy Analyst Rutgers Center for State Health Policy June 28, 2005 Wrapping Around the Part D Benefit: Implications for State Pharmacy Assistance Programs and Low-Income Enrollees

Rutgers Center for State Health Policy June 28, 2005 Acknowledgement Presentation based on: Study of state pharmacy assistance programs funded by The Commonwealth Fund Longitudinal survey of SPAPs Telephone interviews in Spring/Fall 2004 with 17 states re: Medicare coordination of benefit issues and discount card experience. Website with more detailed reports: / Analysis of Part D regulations and operational guidance and SPAP eligibility data in one state. Collaborating Faculty: Stephen Crystal, PhD Jasmine Sia, MD/MPH Dorothy Gaboda, PhD

Rutgers Center for State Health Policy June 28, 2005 Presentation Outline Overview of SPAPs and how they compare with Medicare Part D Options, Opportunities, and Challenges for SPAPs to Wrap around Part D State Case Example

Rutgers Center for State Health Policy June 28, 2005 Program is operational Program enacted but not operational No program enacted or operational * The District of Columbia’s direct benefit program is enacted but not operational. Source: National Conference of State Legislatures’ web site: State Pharmaceutical Assistance Programs, 2004 Edition, November 11, * How Many States Have State Pharmacy Assistance Programs (SPAPs)?

Rutgers Center for State Health Policy June 28, 2005 Source: Trail, T., Fox, K., Cantor, J, Silberberg, M., Crystal, S. State Pharmacy Assistance Programs: A Chartbook. The Commonwealth Fund, New York, NY, August *MD and MN also require an asset test How SPAP Income Eligibility Compares with Medicare Part D and Low-Income Subsidies? ** Percent of FPL MMA Low-Income Subsidy Level 150%

Rutgers Center for State Health Policy June 28, 2005 How SPAP Benefits Compare with Part D and Low-Income Subsidies? Caveat: Cost-sharing and benefits vary by state* Generally… Non-catastrophic Basic Part D cost-sharing > SPAP. Medicare Full Low-Income Subsidies <= SPAPs. Medicare Partial Low-Income Subsidies ?? Generally… Part D drug formularies < SPAPs Except states that limit coverage to drugs for certain conditions (6) or that have PDLs (9). Part D private pharmacy networks <= SPAPs. * For more details on current SPAP cost-sharing see:

Rutgers Center for State Health Policy June 28, 2005 Presentation Outline Overview of SPAPs and how they compare with Medicare Part D Options, Opportunities, and Challenges for SPAPs to Wrap around Part D

Rutgers Center for State Health Policy June 28, 2005 SPAP Options/Opportunities under Medicare Part D If SPAP enrollees enroll in Part D, could offset current state costs CMS estimates that SPAPs will save approximately $600 million/ year. Special privileges for “qualifying” SPAPs Expenses paid by SPAP count toward TrOOP Part D plans required to coordinate benefits/share data SPAP Transitional grants - $62.5 million/yr SPAP Transition Commission. “Qualifying” SPAPs State-only funded drug benefit/ not discount cards Statutory language - “In determining eligibility and amount of assistance, provides such assistance to such individuals in all Part D plans and does not discriminate based on the Part D plan in which they are enrolled.” Final rule interpretation – not only equal assistance, but cannot “steer.” Supplemental coverage options for SPAPs Pay full premium for basic benefit Pay lump sum capped funds toward basic premium, supplemental premium, and/or out-of-pocket costs. Provide wrap-around secondary claim payment coverage.

Rutgers Center for State Health Policy June 28, 2005 Key Concerns/Choices for SPAPs Maintaining/starting state program or terminating/restructuring benefit? Qualified vs. non-qualified SPAP? What/How to Wrap? Premiums, deductibles/cost-sharing in and out of donut hole, formularies, networks Lump sum payment or secondary wrap Getting SPAP Enrollees to Enroll in Part D/LIS Mandate Part D/LIS enrollment Authorized representative Co-branding Intelligent random assignment COB Challenges Once Enrolled

Rutgers Center for State Health Policy June 28, 2005 Methodological Challenges in Assessing Potential Cost-Savings to SPAPs Potential savings driven by enrollment rates in Part D and LIS and, once enrolled, proportion of expenses that will be charged/covered by primary source of payment - No benchmark experience Medicare LIS means-testing totally new Medicare Discount Card program had different rules (but when states left voluntary only 25-50% estimated enrolled in TA, even lower percentage used it) Current utilization/expenditures does not reflect future use/prices Most SPAPs have used minimal cost containment tools Much of Part D-specific information still unknown to states Rebate levels – How much/how they will be passed on Formularies Cost-sharing across tiers

Rutgers Center for State Health Policy June 28, 2005 Rebates as a Percentage of Total SPAP Drug Expenditures, 2003 Source: Sia, J, Fox, K., Trail, T., Crystal, S. State Pharmacy Assistance Programs 2003: A Chartbook, The Commonwealth Fund, publication forthcoming. Notes: Florida, Maine, Michigan, Nevada, Rhode Island, South Carolina, and Wyoming did not provide data on rebate collection. Wisconsin only includes 10 months. Delaware does not include the privately funded Nemours program. Massachusetts includes ingredient cost and dispensing fee. * Indiana and Kansas reported 0% rebates collected. All States = Total rebates divided by total drug expenditures (N=15). ** Rebates as Percentage of Drug Expenditures 65

Rutgers Center for State Health Policy June 28, 2005 Old Programs 1999 N = N = N = N = N = 11 Trends in Annual SPAP Drug Expenditures Per End-of-Year Enrollee, 1999 to 2003 Notes: Old programs are those established prior to 1999 (N = 12), and new programs are those established since 1999 (N = 10). Only programs operational for at least one full year were included in the analysis. Averages represent data from all states that reported for that year – see Legends. New Programs 1999 N = N = N = N = N = 10 71

Rutgers Center for State Health Policy June 28, 2005 Presentation Outline Overview of SPAPs and how they compare with Medicare Part D Options, Opportunities, and Challenges for SPAPs to Wrap around Part D State Case Example

Rutgers Center for State Health Policy June 28, 2005 Methods for Estimating LIS Eligibility Analyzed 2003 eligibility data for SPAP enrollees with incomes below 350% FPL in two distinct programs within one state with different cost-sharing requirements. Assigned enrollees to Medicare benefit category – basic benefit, partial low-income subsidy, full low-income subsidy Estimated assets using income/dividends – assumed 4% interest rate

Rutgers Center for State Health Policy June 28, 2005 Enrollee Characteristics

Rutgers Center for State Health Policy June 28, 2005 Majority of SPAP Enrollees Will Not Qualify for Low Income Subsidies Source: SPAP eligibility data Includes all persons enrolled for any portion of the calendar year.

Rutgers Center for State Health Policy June 28, 2005 Disabled SPAP Enrollees More Likely to Qualify for Low-Income Subsidies Source: SPAP eligibility data, Persons enrolled for any portion of the calendar year.

Rutgers Center for State Health Policy June 28, 2005 LIS Asset Test Greater Barrier for >65 Income Eligible SPAP Enrollees Source: SPAP eligibility data, Includes all persons enrolled for any portion of the calendar year. <135% FPL135%-150%FPL

Rutgers Center for State Health Policy June 28, 2005 Comparison of SPAP Enrollee* Characteristics by LIS Eligibility

Rutgers Center for State Health Policy June 28, 2005 Summary/Policy Implications SPAPs have unique opportunities to wrap around the Medicare benefit but face administrative hurdles. Many low to moderate income SPAP enrollees may not be eligible for Part D full low income subsidies and could benefit from additional assistance. State savings (and ability to wrap or expand to other populations) reliant on getting eligible persons enrolled in LIS and Part D plans. l Transition period of enrolling existing beneficiaries into Part D and LIS likely to be difficult l State budget problems and Part D/SPAP administrative complexities could ‘crowd-out’ many existing programs.